1
|
Koopaei NN, Shademani M, Yazdi NS, Tahmasvand R, Dehbid M, Koopaei MN, Azizian H, Mousavi Z, Almasirad A, Salimi M. Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity. BMC Chem 2022; 16:81. [PMID: 36320042 PMCID: PMC9624014 DOI: 10.1186/s13065-022-00873-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Accepted: 10/04/2022] [Indexed: 11/05/2022] Open
Abstract
Background Compounds possessing urea/thiourea moiety have a wide range of biological properties including anticancer activity. On the other hand, taking advantage of the low toxicity and structural diversity of hydrazone derivatives, they are presently being considered for designing chemical compounds with hydrazone moiety in the field of cancer treatment. With this in mind, a series of novel ureido/thioureido derivatives possessing a hydrazone moiety bearing nitro and chloro substituents (4a–4i) have been designed, synthesized, characterized and evaluated for their in vitro cytotoxic effect on HT-29 human colon carcinoma and HepG2 hepatocarcinoma cell lines. Results Two compounds (4c and 4e) having the chloro phenylurea group hybridized with phenyl hydrazone bearing nitro or chloro moieties demonstrated potent anticancer effect with the IC50 values between 2.2 and 4.8 µM at 72 h. The mechanism of action of compound 4c was revealed in hepatocellular carcinoma cells as an inducer of apoptosis in a caspase-independent pathway. Conclusion Taken together, the current work presented compound 4c as a potential lead compound in developing future hepatocellular carcinoma chemotherapy drugs. Methods The compounds were synthesized and then characterized by physical and spectral data (FT-IR, 1H-NMR, 13C-NMR, Mass). The anticancer activity was assessed using MTT assay, flowcytometry, annexin-V, DAPI staining and Western blot analysis. Graphical Abstract ![]()
Supplementary Information The online version contains supplementary material available at 10.1186/s13065-022-00873-3.
Collapse
Affiliation(s)
- Nasrin Nassiri Koopaei
- grid.411463.50000 0001 0706 2472Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, P.O. Box 1941933111, Tehran, Iran
| | - Mehrasa Shademani
- grid.420169.80000 0000 9562 2611Department of Physiology and Pharmacology, Pasteur Institute of Iran, P.O. Box 1316943551, Tehran, Iran ,grid.411463.50000 0001 0706 2472Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Nasrin Shirzad Yazdi
- grid.411463.50000 0001 0706 2472Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, P.O. Box 1941933111, Tehran, Iran ,grid.412571.40000 0000 8819 4698Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Raheleh Tahmasvand
- grid.420169.80000 0000 9562 2611Department of Physiology and Pharmacology, Pasteur Institute of Iran, P.O. Box 1316943551, Tehran, Iran
| | - Mina Dehbid
- grid.411872.90000 0001 2087 2250Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran
| | - Mansur Nassiri Koopaei
- grid.411705.60000 0001 0166 0922Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design & Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
| | - Homa Azizian
- grid.411746.10000 0004 4911 7066Department of Medicinal Chemistry, School of Pharmacy-International Campus, Iran University of Medical Science, Tehran, Iran
| | - Zahra Mousavi
- grid.411463.50000 0001 0706 2472Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Ali Almasirad
- grid.411463.50000 0001 0706 2472Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, P.O. Box 1941933111, Tehran, Iran
| | - Mona Salimi
- grid.420169.80000 0000 9562 2611Department of Physiology and Pharmacology, Pasteur Institute of Iran, P.O. Box 1316943551, Tehran, Iran
| |
Collapse
|
2
|
Antiproliferative pharmacophore azo-hydrazone analogue BT-1F exerts death signalling pathway targeting STAT3 in solid tumour. Pharmacol Rep 2022; 74:353-365. [PMID: 35001321 DOI: 10.1007/s43440-021-00345-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 11/21/2021] [Accepted: 11/24/2021] [Indexed: 10/19/2022]
Abstract
BACKGROUND Anomalous activation of intra-cellular signalling cascades confers neoplastic properties on malignant cells. The JAK2/STAT3 proteins play a pivotal role in the pathogenesis of most of the solid malignancies. The over expression of STAT3 in these tumours results in an evasion of apoptosis and thereby pathogenesis. Hence, strategy to target STAT3 to regress tumour development is an emerging new concept. As an approach, anti-neoplastic drug, Azo-hydrozone analogue, BT-1F with potential anti-proliferative effect was evaluated to demonstrate its capacity to counteract STAT3 signal with mechanistic approach. METHODS Cell based screening for cytotoxicity was performed through MTT, LDH and Trypan blue. The BT-1F induced anti-clonogenic property by clonogenic assay. The apoptotic capacity was examined by crystal violet staining, flow cytometry, Annexin-FITC, DAPI and TUNEL assay. The altered signalling events were studied using immunoblot. The drug-induced anti-tumour effect was evaluated in an in-vivo solid tumour model and molecular interaction was further validated by in-silico studies. RESULTS The BT-1F exerts chemo-sensitivity specifically against EAC and A549 cells without altering its normal counterpart. The anti-proliferative/anti-clonogenic effect was due to the induction of apoptosis through inhibition of STAT3Tyr705 signal. Eventually downstream signalling proteins p53, Bax, Bad and Bcl-xL were significantly altered. Further in-vivo experimental results validated in-vitro findings. The computational approaches assures the BT-1F efficiency in binding with STAT3. CONCLUSION Systemic validation of STAT3 target drug, BT-1F in in-vitro, in-silico and in-vivo models has promising strategy for solid cancer treatment.
Collapse
|
3
|
Uysal UD, Ercengiz D, Karaosmanoğlu O, Berber B, Sivas H, Berber H. Theoretical and experimental electronic transition behaviour study of 2-((4-(dimethylamino)benzylidene)amino)-4-methylphenol and its cytotoxicity. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2020.129370] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
4
|
Gopal D, Muddebihalkar AG, Skariyachan S, C AU, Kaveramma P, Praveen U, Shankar RR, Venkatesan T, Niranjan V. Mitogen activated protein kinase-1 and cell division control protein-42 are putative targets for the binding of novel natural lead molecules: a therapeutic intervention against Candida albicans. J Biomol Struct Dyn 2019; 38:4584-4599. [PMID: 31625462 DOI: 10.1080/07391102.2019.1682053] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Candida albicans, fungal yeast causes several lethal infections in immune-suppressed patients and recently emerged as drug-resistant pathogens worldwide. The present study aimed to screen putative drug targets of Candia albicans and to study the binding potential of novel natural lead compounds towards these targets by computational virtual screening and molecular dynamic (MD) simulation. Through extensive analysis of mitogen-activated protein kinase (MAPK) signalling pathways, mitogen-activated protein kinase-1 (HOG1) and cell division control protein-42 (CDC42) genes were prioritized as putative targets based on their virulent functions. The three-dimensional structures of these genes, not available in their native forms, were computationally modeled and validated. 76 lead molecules from various natural sources were screened and their drug likeliness and pharmacokinetic features were predicted. Among these ligands, two lead molecules that demonstrated ideal drug-likeliness and pharmacokinetic features were docked against HOG1 and CDC42 and their binding potential was compared with the binding of conventional drug Fluconazole with their usual target. The prediction was computationally validated by MD simulation. The current study revealed that Cudraxanthone-S present in Cudrania cochinchinensis and Scutifoliamide-B present in Piper scutifolium exhibited ideal drug likeliness, pharmacokinetics and binding potential to the prioritized targets in comparison with the binding of Fluconazole and their usual target. MD simulation showed that CDC42-Cudraxanthone-S and HOG1-Scutifoliamide-B complexes were exhibited stability throughout MD simulation. Thus, the study provides significant insight into employing HOG1 and CDC42 of MAPK as putative drug targets of C. albicans and Cudraxanthone-S and Scutifoliamide-B as potential inhibitors for drug discovery.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Dharshini Gopal
- Department of Biotechnology, Dayananda Sagar College of Engineering, Kumaraswamy Layout, Bengaluru, India
| | - Aditi G Muddebihalkar
- Department of Biotechnology, Dayananda Sagar College of Engineering, Kumaraswamy Layout, Bengaluru, India.,Department of Biotechnology, RV College of Engineering, Bangalore, Karnataka, India
| | - Sinosh Skariyachan
- Department of Biotechnology, Dayananda Sagar College of Engineering, Kumaraswamy Layout, Bengaluru, India
| | - Akshay Uttarkar C
- Department of Biotechnology, RV College of Engineering, Bangalore, Karnataka, India
| | - Prinith Kaveramma
- Department of Biotechnology, Dayananda Sagar College of Engineering, Kumaraswamy Layout, Bengaluru, India
| | - Ulluvangada Praveen
- Department of Biotechnology, Dayananda Sagar College of Engineering, Kumaraswamy Layout, Bengaluru, India
| | - Roshini Ravi Shankar
- Department of Biotechnology, Dayananda Sagar College of Engineering, Kumaraswamy Layout, Bengaluru, India
| | - Tejaswini Venkatesan
- Department of Biotechnology, Dayananda Sagar College of Engineering, Kumaraswamy Layout, Bengaluru, India
| | - Vidya Niranjan
- Department of Biotechnology, RV College of Engineering, Bangalore, Karnataka, India
| |
Collapse
|